Mikhail Blagosklonny, Emerging Therapies In Anti-Aging Prevention

Mikhail Blagosklonny attended First Pavlov State Medical University in Saint Petersburg, Russia, where he earned his Master’s and PHD degrees. Using his education as a backdrop, Blagosklonny has become a veteran of experimental research in oncology and life extension.

Related to his work is the discovery of a drug that has shown promising results in reversing, slowing or delaying the aging process. The drug is, Everolimus (Rapamycin) is classified as a first generation mTOR inhibitor. Blagosklonny revealed the off label use of Everolimus just may yield or halt “random molecular damage.” That’s not only stopping the cellular breakdown related to aging, but it may also be used to treat conditions such as metabolic disorders, cancer and cardiovascular diseases. View Mikhail’s profile on Google Scholar

Blagosklonny sees the use of the oncology pathway, Rapamycin, in the correct dose, as the key to improving the physiological factors that cause aging. The participants in a study that Mikhail Blagosklonny examined went from having “adult” immunity cells back to “infant” immunity cells. Rapamycin was shown to prevent the degenerative effects of aging. It should be pointed out that in the study that Blagosklonny discussed, the participants were all normal, healthy adults. Beyond the study, Blagosklonny is interested in development of Rapamycin as an anti-aging treatment.

In addition to his research work concerning Rapamycin as the anti-aging drug of the future, Mikhail Blagosklonny works at the Roswell Park Cancer Institute. As a Professor and a Scientist, he concentration field is Oncology. The process that lead to Blagosklonny to his research area, began in 2002, with appointment as a Professor at New York Medical College. From there he would go on to tenure as a senior scientist at Ordway Research Institute. Then in 2009, he joined the Roswell Institute. The primary area that he focuses on with his studies is how to achieve the best outcome for patients with cancer.

The discovery of Rapamycin as an anti-aging therapy, came from its intended use as a cancer treatment drug. Blagosklonny saw that the drug could potentially prevent cellular damage from occurring. Then in the study, it was revealed with published findings that the drug also could have an effect on reversing the aging process. This potential was documented as, TOR Signaling, and it refers to an array of factors that influence the selective process of normal cell production. Science has already demonstrated the value of Rapamycin in cancer treatment, but Mikhail Blagosklonny research indicates that it can also provide life extending benefits.

Read more: http://gettingstronger.org/tag/mikhail-blagosklonny/

According to Mikhail Blagosklonny the cancer drug, Rapamycin can serve many roles in medical treatment. It could fill the gaps from infancy to old age preventing the cellular breakdown of immunity. Only a few years ago, this would have seemed far off in the future, Blagosklonny continued research has shown direct promise for current outcomes. His studies reveal that Rapamycin may have potential benefit for the prevention of aging in a well-developed population. Meaning that both healthy people and those suffering from health disorders could see prevention of cellular damage.

Minra Therapeutics Appoints Clay Siegall to Its Board

Renowned bio technologist Clay Siegall, has been appointed to the board of Minra Therapeutics. Dr. Siegall will serve the board as an autonomous director. Founded in 2007, the Texas-based company focuses on the advancement of microRNA in the field of biotechnology. For the past few years, it has also been dedicated to cancer research, an area that Dr. Siegall is well-versed in. his experience and expertise will therefore, boost Minra’s efforts.

Since its formation, Minea Therapeutics has gained market dominance due to its ability to develop products that address the needs of the market. The firm boosts the services of renowned researchers, who play a significant role in the advancement of top-notch products. The dedication that it has towards innovation has seen it come up with products that have fully been integrated into cancer therapies offered throughout the world. With the addition of Dr. Siegall, Minra Therapeutics boasts an experienced and competent board, which will ultimately guide it towards greater heights.

Important Notes about ClaySiegall

Dr. Siegall is one of the most prolific biotechnologists in the United States. His name is synonymous with Seattle Genetics, a biotechnology firm that he co-founded in 1998 with the aim of advancing cheaper, advanced, and more pragmatic cancer therapies. Siegall’s proactive approach to research and entrepreneurship has seen him become the company’s bedrock. He not only leads its business operations, but also its scientific research teams. Therapies that have emerged from the company’s remarkable production line are currently used to treat cancer in over 70 countries.

Seattle Genetics was catapulted into the limelight following the advancement of world-renowned cancer therapy, ADCETRIS, which is its top product. The firm has similarly produced a number of therapies, which are available in different parts of the world. However, its ascent to the top of the biotechnology world has been buoyed by Dr. Siegall’s extensive networks, which have enabled him to seek funding from various sources. Over 675 million dollars has been channeled towards research, and the construction of the ultra-modern facility in Washington, which houses the company. Dr. Siegall studied at George Washington University, and the University of Maryland. He is a board director of several notable pharmaceutical companies.